Journal of ISSN: 2376-0060JLPRR

Lung, Pulmonary & Respiratory Research
Proceeding
Volume 3 Issue 1 - 2016
New Drugs in Lung Cancer Chemotherapy
Attapon Cheepsattayakorn1,2,3* and Ruangrong Cheepsattayakorn4
1Editor-in-Chief, Journal of Lung, Pulmonary and Respiratory Research, USA
210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
35th Office of Disease Prevention and Control, Ratchaburi, Department of Disease Control, Ministry of Public Health, Thailand
4Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Received: February 14, 2016 | Published: March 02, 2016
*Corresponding author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100 Thailand, Tel: 66 53 140767; 66 53 276364; Fax: 66 53 140773; 66 53 273590; Email: ;
Citation: Cheepsattayakorn A, Cheepsattayakorn R (2016) New Drugs in Lung Cancer Chemotherapy. J Lung Pulm Respir Res 3(1): 00072. DOI: 10.15406/jlprr.2015.03.00072

Abstract

The new chemotherapeutic agents offer equally or more effective palliation, with more favorable therapeutic index and reduced toxicity. Despite advances performed in detecting and treating lung cancer, its prognosis remains grim. Having only 50% chance of five-year survival even patients whose lung cancer are caught at their earliest stage. Uniquely targeted therapies with specific inhibitor drugs such as crizotinib is due to the discovery of a number of lung cancer-molecular alterations. Crizotinib, the first inhibitor of both C-Mesenchymal-Epidermal-Epithelial-Transition receptor kinase and anaplastic lymphoma kinase has been approved for the treatment of anaplastic-lymphoma-kinase-positive non-small-cell-lung cancer in the United States. TOR (Target of Rapamycin) kinase inhibitor plus erlotinib or a cytidine analog for treatment of non-small-cell lung cancer was recently introduced. Treatment with EGFR (Epidermal Growth Factor Receptor)-TKIs (Tyrosine Kinase Inhibitors) (gefitinib, erlotinib) is currently recommended for the first-line treatment regimen of advanced non-small-cell lung cancer. Better median survival of gemcitabine plus cisplatin, vindesine plus cisplatin, gemcitabine plus carboplatin, and mitomycin plus vinblastine plus cisplatin regimens as the second-line drugs was demonstrated in treating advanced-stage non-small-cell lung cancer in comparison to a single agent chemotherapy with docetaxel. Currently, erlotinib, pemetrexed, and docetaxel are the only approved chemotherapeutic agents for second-line chemotherapy in unselected patients with non-small-cell lung cancer. In 2013, many compounds, such as nitrobenzamide, benzodiazepine, cyclopropane, taxane, purine, pyrrolopyrimidine, arylamino purine, and quinazoline were introduced in treating non-small-cell lung cancer. A piperidine and piperazine derivative as Sobitan-Mono-Oleate antagonists for treating small-cell lung cancer was recently introduced as well as picoplatin and arsenic trioxide. Other more innovative strategies may further broaden our ability to effectively treat these patients and expand our current ability to control this disease, palliative symptoms, prolong survival, and improve overall quality of life. This poor prognosis is due to in part to the cancer’s ability to resist chemotherapy. Finally, a number of questions remain to be answered, such as: are combinations a regimen superior to single-agent chemotherapy, are three drug combination (or four) better than two and does dose intensity have a role in advanced non-small-cell lung cancer, etc.

© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at http://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy